

**AHNCI Neurologic Oncology Program Tumor Board**

Friday, March 6, 2020

12:00-1:00 p.m.

Jho Conference Room, 6th Floor, AGH

Join Zoom Meeting

<https://zoom.us/j/519670691>

Meeting ID: 519 670 691

Dial by your location

+1 646 558 8656

**Cases to be discussed**

|  |  |  |  |
| --- | --- | --- | --- |
| **Case** | **De-identified patient** | **Reason** | **Presenter** |
| 1 | MN MRN: 166080 | 35-year-old male status post right frontal craniotomy in 2006 for who grade 2 oligo astrocytoma by Dr. Quigley after presentation with incidental blurred vision requiring change in refraction.  MRI of brain from November 2019 revealed increase T2 FLAIR changes prompting short interval MRI from March 2, 2020 with stable FLAIR changes but has increased overall since 2017.  Tumor board evaluation for recommendation for possible surgery for progression of disease. | AY |
| 2 | BR MRN: 838424 | Patient is a 5-year-old gentleman with history of resection of tumor followed by radiation is 6-month-old at Children's Hospital of Pittsburgh with development of multiple meningiomas status post resection in 2011 by Dr. Aziz with development of external hydrocephalus with current Medtronic strata 2 ventriculoperitoneal shunt currently set at 1.0 for discussion for increasing size of right CP angle mass. | AY |
| 3 | DM MRN:  225475 | 61 y/o female with newly diagnosed GBM currently admitted to AGH s/p resection by Dr. Yu on 2/13/20. Patient will need placement in SNF or rehab facility upon discharge. Family still deciding on whether or not to pursue treatment with radiation at this time. Presenting to discuss plan with radiation oncology | TR |
| 4 | BH MRN:  10375300 | 36 y/o female with Left Glioblastoma; WHO Grade IV, MGMT Unmethylated (UPMC ), IDH Wild type, diagnosed 7/14/2015, transition from Anaplastic Astrocytoma WHO Grade III to GBM 10/25/2017. Progressive disease noted on MRI Brain 2/11/20. Patient candidate for surgery with Chemo ID per Dr Xu. Presenting to discuss plan for surgery | TR |
| 5 | EN MRN:  10411292 | 59 y/o male with Left Parietal Glioblastoma, WHO Grade IV, MGMT unmethylated (0.04), IDH Wild type, diagnosed 6/6/2019. Possible abcess noted on lumbar MRI 3/4/20. Planning for LP next week. Presenting to review imaging | TR |
| 6 | KC MRN:  10628561 | 23 y/o male with Left midbrain/thalamus Glioblastoma, WHO Grade 4, IDH-wild type, MGMT unmethylated,diagnosed 12/6/2016. Possibility of recurrent disease noted on PET Brain 3/4/20. Presenting to review imaging and discuss possible treatment with radiation oncology | TR |
| 7 | DL MRN:  10053764 | 59 y/o male with Right Temporal Glioblastoma, WHO Grade IV, IDH-Wildtype, MGMT Methylated (76.30), diagnosed 5/28/2019. Presenting to review MRI Brain 3/6/20. | TR |
| 8 | WH MRN:  10227384 | 60 y/o male with newly diagnosed multifocal GBM. Patient may be candidate for proton therapy at Johns Hopkins. Presenting to discuss plan for treatment. | TR |
| 9 | KE MRN: 4161651 | Brain metastases | CH |
| 10 | BP MRN: 16905 |  | CH |
| 11 | JA MRN: 1287739 | MRI Brain done 3/4/20 | CH |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

AHN CME Credit

**TEXT 412-301-9919**save this number to your contacts–  
will use this **same** number every week to text your attendance

**Today’s SMS Code: GUSTEG**

You must text within 24 hours of the start of tumor board. You will receive a text receipt and a link to confirm attendance and receive credit

Objectives: Upon completion of this activity, participants will have a better understanding of decision-making for complex Neurologic Oncology and be armed with clinical pathways to improve care.

Accreditation: Allegheny General Hospital is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credit Designation Statement:Allegheny General Hospital designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit(s)™*.  Physicians should claim only the credit commensurate with the extent of their participation in this activity.

Disclosure: In accordance with the Accreditation Council for Continuing Medical Education (ACCME) and the policy of Allegheny General Hospital, presenters must disclose all relevant financial relationships, which in the context of their presentation(s), could be perceived as a real or apparent conflict of interest, (e.g., ownership of stock, honoraria or consulting fees). Any identifiable conflicts will be resolved prior to the activity. Any such relationships will be disclosed to the learner prior to the presentation(s).

Moderators and Presenters: Tulika Ranjan, MD and Stephen Karlovits, MD has nothing to disclose